SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pharma sector stocks tumble amid reports of imminent tariffs by Trump administration

04 Apr 2025 Evaluate

Pharmaceutical sector stocks slipped following reports that the Trump Administration will soon announce tariffs on pharma imports and emphasised that the measures will be ‘unprecedented’.

Aurobindo Pharma is currently trading at Rs. 1112.45, down by 63.60 points or 5.41% from its previous closing of Rs. 1176.05 on the BSE. The scrip opened at Rs. 1175.00 and has touched a high and low of Rs. 1176.60 and Rs. 1049.85 respectively. So far 140673 shares were traded on the counter.

Cipla is currently trading at Rs. 1415.25, down by 79.90 points or 5.34% from its previous closing of Rs. 1495.15 on the BSE. The scrip opened at Rs. 1499.25 and has touched a high and low of Rs. 1499.25 and Rs. 1390.35 respectively. So far 40021 shares were traded on the counter. 

Lupin is currently trading at Rs. 1977.75, down by 116.75 points or 5.57% from its previous closing of Rs. 2094.50 on the BSE. The scrip opened at Rs. 2094.35 and has touched a high and low of Rs. 2094.35 and Rs. 1918.20 respectively. So far 51714 shares were traded on the counter.

Sun Pharmaceutical Industries is currently trading at Rs. 1709.00, down by 61.10 points or 3.45% from its previous closing of Rs. 1770.10 on the BSE. The scrip opened at Rs. 1772.10 and has touched a high and low of Rs. 1781.70 and Rs. 1658.00 respectively. So far 88049 shares were traded on the counter.

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×